The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1228
February 13, 2006
View Complete Issue         Table of Contents 2019 
Nelarabine (Arranon) for T-Cell Acute Lymphoblastic Leukemia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Nelarabine (Arranon) for T-Cell Acute Lymphoblastic Leukemia
February 13, 2006 (Issue: 1228)
Nelarabine (Arranon - GlaxoSmithKline), a prodrug of the deoxyguanosine analog 9-β-D-arabinofuranosylguanine (ara-G), has been approved by the FDA for treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Nelarabine (Arranon) for T-Cell Acute Lymphoblastic Leukemia
Article code: 1228b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.